Division of Bacterial Respiratory Infections, Center for Infectious Diseases, National Institute of Health, Korea Centers for Disease Control and Prevention, 5 Nokbun-Dong, Eunpyung-Ku, Seoul 122-701, South Korea.
Antimicrob Agents Chemother. 2010 Jan;54(1):65-71. doi: 10.1128/AAC.00966-09. Epub 2009 Nov 2.
Antimicrobial susceptibility patterns and beta-lactam resistance mechanisms of 544 Haemophilus influenzae isolates through the nationwide Acute Respiratory Infections Surveillance (ARIS) network in Korea during 2005 and 2006 were determined. Resistance to ampicillin was 58.5%, followed by resistance to cefuroxime (23.3%), clarithromycin (18.7%), cefaclor (17.0%), amoxicillin-clavulanate (10.4%), and chloramphenicol (8.1%). Levofloxacin and cefotaxime were the most active agents tested in this study. beta-Lactamase production (52.4%) was the main mechanism of ampicillin resistance, affecting 96.1% of TEM-1-type beta-lactamase. According to their beta-lactam resistance mechanisms, all isolates were classified into the following groups: beta-lactamase-negative, ampicillin-sensitive (BLNAS) strains (n = 224; 41.5%); beta-lactamase-positive, ampicillin-resistant (BLPAR) strains (n = 255; 47.2%); beta-lactamase-negative, ampicillin-resistant (BLNAR) strains (n = 33; 6.1%); and beta-lactamase-positive, amoxicillin-clavulanate-resistant (BLPACR) strains (n = 28; 5.2%). Among the BLNAR and BLPACR strains, there were various patterns of multiple-amino-acid substitutions in penicillin-binding protein 3. Particularly, among BLNAR, group III isolates, which had three simultaneous substitutions (Met377Ile, Ser385Thr, and Leu389Phe), were identified for the first time in Korea. Three group III strains displayed the highest MIC of cefotaxime (1 to 2 mug/ml). The results indicate the importance of monitoring a changing situation pertaining to the increase and spread of BLNAR and BLPACR strains of H. influenzae for appropriate antibiotic therapy for patients with respiratory tract infections in Korea.
2005 年至 2006 年,通过韩国全国急性呼吸道感染监测(ARIS)网络,确定了 544 株流感嗜血杆菌的抗菌药物敏感性模式和β-内酰胺类耐药机制。对氨苄西林的耐药率为 58.5%,其次是对头孢呋辛(23.3%)、克拉霉素(18.7%)、头孢克洛(17.0%)、阿莫西林-克拉维酸(10.4%)和氯霉素(8.1%)的耐药率。左氧氟沙星和头孢噻肟是本研究中活性最强的药物。β-内酰胺酶的产生(52.4%)是氨苄西林耐药的主要机制,影响了 96.1%的 TEM-1 型β-内酰胺酶。根据其β-内酰胺类耐药机制,所有分离株分为以下几类:β-内酰胺酶阴性、氨苄西林敏感(BLNAS)株(n=224;41.5%);β-内酰胺酶阳性、氨苄西林耐药(BLPAR)株(n=255;47.2%);β-内酰胺酶阴性、氨苄西林耐药(BLNAR)株(n=33;6.1%);β-内酰胺酶阳性、阿莫西林-克拉维酸耐药(BLPACR)株(n=28;5.2%)。在 BLNAR 和 BLPACR 株中,青霉素结合蛋白 3 存在多种氨基酸取代的模式。特别是,在 BLNAR 中,首次在韩国发现了具有三个同时取代(Met377Ile、Ser385Thr 和 Leu389Phe)的 III 组分离株。三组 III 株对头孢噻肟的 MIC 值最高(1 至 2 微克/毫升)。结果表明,对于韩国呼吸道感染患者的适当抗生素治疗,监测 BLNAR 和 BLPACR 流感嗜血杆菌菌株的增加和传播情况非常重要。